July 29, 2019 | Letisia Marquez
City of Hope has been named the best cancer hospital in the West by U.S. News & World Report’s 2019-20 Best Hospitals: Specialty Ranking. This marks the 13th consecutive year it has been distinguished as one of the nation’s elite cancer hospitals.
Groundbreaking new CAR T cell trial opens for patients with breast cancer that has spread to the brain
October 30, 2018 | Letisia Marquez
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
Meet Our CAR T Team: Christine Brown, Ph.D.
January 26, 2018 | Abe Rosenberg
Christine Brown, Ph.D., co-leads the T Cell Therapeutics Research Laboratory, along with Stephen J. Forman, M.D., which to date has treated more than 100 patients in seven clinical trials, with aggressive goals of opening four new clinical studies within the year.
MEET OUR DOCTORS: Behnam Badie on why ‘being a neurosurgeon is not enough’
November 2, 2017 | Denise Heady
Driven in part by the plight of his patients and his father, chief of neurosurgery Behnam Badie, M.D., spends nearly as much time in the laboratory as he does in the operating room. He wants to help not just today's patients, but tomorrow's.
City of Hope researchers find CAR T cell therapy effective in treatment of glioblastoma
July 17, 2017 | Denise Heady
City of Hope researchers have found that using CAR T therapy, a type of immunotherapy, can be effective in the treatment of glioblastoma — one of the most aggressive brain tumors known to medicine.
Behnam Badie awarded $2.1 million R01 grant to help patients with aggressive brain tumors
April 24, 2017 | Denise Heady
What started as an unplanned lunch date has turned into a potential breakthrough in the treatment of gliomas – a fast-growing, and often deadly type of brain tumor.
CIRM Symposium: New Developments in Stem Cell Therapies
March 28, 2017 | Michael Easterling
The stories of patients who have benefited from stem cell therapies funded by the California Institute for Regenerative Medicine (CIRM) were the focus of the second symposium of the institute’s Alpha Stem Cell Clinics Network.